» Articles » PMID: 25890194

Enduring Effects of Tacrine on Cocaine-reinforced Behavior: Analysis by Conditioned-place Preference, Temporal Separation from Drug Reward, and Reinstatement

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2015 Apr 19
PMID 25890194
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Previous work by our laboratory has shown that tacrine can produce long-lasting reductions in cocaine-reinforced behavior, when administered to rats as daily intravenous infusions over four days. Tacrine causes dose-related liver toxicity in different species, and its manufacture for human use was recently discontinued. This study was conducted to further characterize its actions on cocaine reward. Cocaine-experienced animals that had no contact with drug over one week resumed self-administration at levels similar to their initial baseline. When tacrine was administered over four days which were preceded and followed by washout periods to allow elimination of cocaine and tacrine respectively, subsequent cocaine self-administration was attenuated by more than one-half. Tacrine administered at 10 mg/kg-day as a chronic infusion by osmotic pump did not modify cocaine-induced increases in locomotor activity or conditioned-place preference. In rats that exhibited persistent attenuation of cocaine-self-administration after receiving tacrine, cocaine-induced reinstatement was also attenuated. No changes in plasma measures of renal or hepatic function were observed in rats receiving tacrine. In conclusion, pretreatment with tacrine can decrease cocaine-motivated behavior measured by self-administration or reinstatement, but not conditioned-place preference. Reductions in cocaine self-administration following pretreatment with tacrine do not require direct interaction with cocaine and are not secondary to either liver or kidney toxicity.

Citing Articles

Effects of acute and repeated administration of the selective M PAM VU0152099 on cocaine versus food choice in male rats.

Thomsen M, Crittenden J, Lindsley C, Graybiel A Addict Biol. 2022; 27(2):e13145.

PMID: 35229940 PMC: 9162150. DOI: 10.1111/adb.13145.


The muscarinic agonist pilocarpine modifies cocaine-reinforced and food-reinforced responding in rats: comparison with the cholinesterase inhibitor tacrine.

Grasing K, Xu H, Idowu J Behav Pharmacol. 2019; 30(6):478-489.

PMID: 30724803 PMC: 6679828. DOI: 10.1097/FBP.0000000000000472.


Effects of muscarinic M and M acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning.

Stoll K, Hart R, Lindsley C, Thomsen M Psychopharmacology (Berl). 2017; 235(3):815-827.

PMID: 29250738 PMC: 6472894. DOI: 10.1007/s00213-017-4797-0.

References
1.
Grasing K, Yang Y, He S . Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition: different effects of donepezil and rivastigmine. Behav Pharmacol. 2011; 22(1):58-70. DOI: 10.1097/FBP.0b013e3283428cd8. View

2.
Elkashef A, Kahn R, Yu E, Iturriaga E, Li S, Anderson A . Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012; 107(7):1297-306. PMC: 3331916. DOI: 10.1111/j.1360-0443.2011.03771.x. View

3.
Alhainen K, Helkala E, Reinikainen K, Riekkinen Sr P . The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect. 1993; 5(3):185-92. DOI: 10.1007/BF02257673. View

4.
Wagstaff A, McTavish D . Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging. 1994; 4(6):510-40. DOI: 10.2165/00002512-199404060-00006. View

5.
Madden S, Spaldin V, Park B . Clinical pharmacokinetics of tacrine. Clin Pharmacokinet. 1995; 28(6):449-57. DOI: 10.2165/00003088-199528060-00003. View